Espinoza TM, Edwards CM

Language: Spanish
References: 19
Page: 33-38
PDF size: 264.28 Kb.

ABSTRACT

Kawasaki Syndrome is an acute multi-organ vasculitis, whose etiology remains incompletely understood; this illness primarily affects infants and young children. It was originally described by Dr. Tomisaku Kawasaki in Japan, since 39 years ago. Since then, KS has been recognized worldwide in children of every racial group, this disease is characterized by fever, bilateral nonexudative conjunctivitis, polymorphous rash, erythema of the lips and oral mucosa, extremity swelling and/or erythema of the palms and soles and cervical lymphadenophaty. Because of that the diagnosis is based on history and physical examination. The symptoms of Kawasaki syndrome are not unique and diagnosis can be difficult. Coronary artery abnormalities are developed in 15 to 25% of untreated children with this disease. The coronary arteries may show evidence of panarteritis, dilatation or aneurysm formation and may lead to ischemic heart disease or suddenly death. Indeed, Kawasaki Disease is now considered one of the two major causes of acquired heart disease in children, overcoming rheumatic fever in many parts of the world.

REFERENCES

1. Apuy. JJ. Enfermedad de Kawasaki. 2003; 564:109-113.

2. Brogan P, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposal for future research. Arch Dis Child 2002;86:286-292.

3. Burns JC, et al. Kawasaki Disease: a brief history. Pediatrics 2000; 106(2): 27.

4. Burns JC, Glodé M. kawasaki syndrome. The Lancet 2004; 364: 533-44.

5. Fong N.C, et al. Evaluation of the Eficacy of Treatment of Kawasaki Disease Before Day 5 of Illness Pediatr Cardiol 2004;25:31-34.

6. Han RK, et al. Recognition and management of Kawasaki disease. CMAJ. 2000 Mar 21;162(6):807-12.

7. Jibiki Toshiaki, et al. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease. Eur J Pediatr 2004:163: 229–233.

8. Krasovec. S, et al. Enfermedad de Kawasaki, evaluación inmunològica de 26 casos. Medicina (Buenos Aires) 2001; 61:8-14.

9. Kuijpers TW, et al. Longstanding obliterative panarteritis in Kawasaki disease: lack of cyclosporine A effect. Pediatrics. 2003 Oct;112(4):986-92.

10. Martínez Ruiz, et al. Incidencia y características clínicas de la enfermedad de Kawasaki. An Pediatr. 2003; 59: 323-327.

11. Meissner HC, et al. Kawasaki syndrome: where are the answers? Pediatrics. 2003 Sep;112(3 Pt 1):672-6.

12. Okada T, et al., Noninvasive assessment of the early progression of atherosclerosis in adolescents with Kawasaki disease and coronary artery lesions. Pediatrics 2003;107: 1095–99.

13. Prego, Javier. Enfermedad de Kawasaki. Arch Pediatr. 2003; 74:99-113.

14. Rowley AH, et al. Kawasaki syndrome. Pediatr Clin North Am. 1999 Apr;46(2):313-29.

15. Rozo J, et al. Kawasaki disease in the adult: a case report and review of the literature.Tex Heart Inst J. 2004;31(2):160-4.

16. Ruey-Kang R, et al. Epidemiologic characteristics of children hospitalized for Kawasaki disease in California. Pediatr Infect Dis J 2002;21:1150-5.

17. Terai M, et al. Prognostic impact of vascular leakage in acute Kawasaki disease. Circulation. 2003 Jul 22;108(3):325-30.

18. Yamamoto L, et al. Kawasaki Disease. Pediatric Emergency Care. 2003; 6: 422-424.

19. You Bin D, et al. Impaired endothelial fuction in the brachial artery after Kawasaki disease and the effects of intravenous administration of vitamin C. Pediatr Infect Dis J. 2003; 22: 34-39.